Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study.

MLA

Aussedat, Guillaume, et al. “Rituximab in Combination with Adapted-Dose of Ifosfamide and Etoposide as Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study.” Leukemia & Lymphoma, vol. 63, no. 3, Mar. 2022, pp. 599–607. EBSCOhost, https://doi.org/10.1080/10428194.2021.1998483.

APA

Aussedat, G., Maucort-Boulch, D., Rey, P., Safar, V., Karlin, L., Elsensohn, M. H., Bachy, E., Lebras, L., Favier, B., Vantard, N., Ghergus, D., Golfier, C., Sesques, P., Lazareth, A., Lequeu, H., Ferrant, E., Salles, G., Nicolas-Virelizier, E., & Ghesquieres, H. (2022). Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study. Leukemia & Lymphoma, 63(3), 599–607. https://doi.org/10.1080/10428194.2021.1998483

Chicago

Aussedat, Guillaume, Delphine Maucort-Boulch, Philippe Rey, Violaine Safar, Lionel Karlin, Mad Helenie Elsensohn, Emmanuel Bachy, et al. 2022. “Rituximab in Combination with Adapted-Dose of Ifosfamide and Etoposide as Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study.” Leukemia & Lymphoma 63 (3): 599–607. doi:10.1080/10428194.2021.1998483.